Compare

Two terms, side by side

Pick any two terms to see definitions, context, pitfalls, and sources in parallel.

Investment & Finance

Mergers and Acquisitions(M&A)

In one line

Transactions in which one company acquires or combines with another — the dominant MedTech exit path, typically a strategic acquisition by an established player.

Definition

Mergers and Acquisitions (M&A) is the umbrella term for transactions where one company acquires or combines with another via stock purchase, asset purchase, merger, or tender offer. In MedTech, strategic acquisitions by established players (Medtronic, J&J MedTech, Boston Scientific, Stryker, Abbott, Edwards) account for the large majority of venture exits. Deal structures commonly include upfront cash, contingent value rights (CVRs) tied to FDA approval or revenue milestones, and earn-outs.

Why it matters

MedTech M&A multiples vary widely by category: 4-8x revenue is typical for established players; 6-15x revenue or milestone-based earn-outs for high-growth platforms; pre-revenue deals are valued on probability-weighted future revenue.

Common pitfalls

•Accepting a high headline price weighted heavily toward earn-outs that buyers can disincentivize post-close.
•Skipping pre-clearance HSR analysis on cross-border or category-leading deals.

Sources

FTC — Hart-Scott-Rodino Filing · FTC
16 CFR 801 — Coverage Rules (HSR) · eCFR
PitchBook - MedTech Coverage · PitchBook

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.